Ozempic for Kidney Protection: Approved Use, Dosing and FLOW

HealthRX.com

Ozempic is approved to lower kidney risk in type 2 diabetes

18.7%FLOW primary kidney composite in the semaglutide groupSource: pubmed.ncbi.nlm.nih.gov

Print or save as PDF

Key numbers

See the public record for Semaglutide

At a glance

  • FDA status / Approved indication in adults with type 2 diabetes and CKD (Ozempic injection) [1]
  • Dose for the kidney indication / 1 mg once weekly, after at least 4 weeks at 0.5 mg [1]
  • FLOW trial / 3,533 adults with type 2 diabetes and CKD; median follow-up 3.4 years [2]
  • Primary kidney composite / 18.7% vs 23.2%; HR 0.76 (95% CI 0.66 to 0.88) [2]
  • eGFR range studied / 25 to 75 mL/min/1.73 m² [2]
  • Renal dose adjustment / None recommended in the label [1]
  • Trial stopped early / Yes, at a prespecified interim analysis [2]
  • Oral semaglutide / Label covers glycemic control and CV risk, not kidney outcomes [3]

Is Ozempic approved for kidney protection?

Yes, for one specific group. The Ozempic label effective 2026-06-01 lists three indications: improving glycemic control in adults with type 2 diabetes; reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [1]. Ozempic has no weight-loss indication — that belongs to Wegovy [1].

So a patient with type 2 diabetes and CKD being prescribed semaglutide for kidney protection is inside the approved label, not outside it. The kidney indication is written for adults with type 2 diabetes and chronic kidney disease, so it does not cover people without type 2 diabetes [1].

What the FLOW trial found

FLOW randomized 3,533 adults with type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo [2]. Entry required either an eGFR of 50 to 75 with a urine albumin-to-creatinine ratio above 300 and below 5,000, or an eGFR of 25 to below 50 with a ratio above 100 and below 5,000 [2]. Median follow-up was 3.4 years, and the trial was stopped early at a prespecified interim analysis [2].

The primary outcome — kidney failure, a 50% or greater reduction in eGFR, or death from kidney or cardiovascular causes — occurred in 18.7% of the semaglutide group and 23.2% of the placebo group (331 versus 410 first events; HR 0.76, 95% CI 0.66 to 0.88) [2]. Cardiovascular death was lower (HR 0.71), major adverse cardiovascular events occurred in 12.0% versus 14.4% (HR 0.82), and all-cause death in 12.8% versus 15.8% (HR 0.80) [2]. Serious adverse events were reported in 49.6% versus 53.8% [2].

One subgroup result matters when weighing options: benefit was not evident in the few patients who were already taking an SGLT2 inhibitor at baseline [2].

What people on Reddit report

Members of a CKD forum who started Ozempic and describe retesting kidney function, with reported changes and mixed views on whether the drug is safe for kidneys.

Past_Cardiologist597 · CKD

About 6ish weeks later on retesting my egfr went up and now another month later my numbers are up again.

Started Ozempic for diabetes after a kidney diagnosis and reports that kidney function test results improved on retesting.

Read the source discussion

McLadyK · CKD

My egfr also shot up and I went from stage 3 to upper 1. I hope the anecdotal evidence is actually released in a study soon!

Reports a large rise in kidney function on Ozempic and wants formal study results to confirm it.

Read the source discussion

IcyAd8213 · CKD

I'm diagnosed 3A and started 5 weeks ago. Going to test again next week and I'd be thrilled to lower my egfr. Have lost 8 pounds with some side effects, but managing them. Will let everyone know if I see improvement or change with my tests!

Recently started Ozempic, plans to retest kidney numbers, and reports weight loss and side effects being managed.

Read the source discussion

RedditNon-Believer · CKD

I've read of such studies, but my nephrologist is hesitant to try it because these medications can possibly damage kidneys. Not a good risk for someone already dialyzing.

Says their kidney specialist is hesitant to use the drug because of possible kidney harm, especially in people on dialysis.

Read the source discussion

Dr Sean Hashmi on why the FLOW trial matters for kidney protection

Dr Sean Hashmi argues that the FLOW trial changed the standard of care for diabetic kidney disease. He says semaglutide was so clearly protective that the trial was stopped early, and that it changed the course of kidney decline rather than only slowing it a little. In his view, the benefit stacks on top of ACE inhibitors, ARBs and SGLT2 inhibitors, so these therapies are layered rather than chosen between. He credits part of the effect to calming the low-grade inflammation that drives kidney scarring, something insulin never touched. He urges patients to ask their doctor for a urine albumin to creatinine test and to ask directly whether semaglutide is right for them. He also stresses planning for dehydration and protecting muscle with resistance training and adequate protein.

Who is speaking?

Dr. Sean Hashmi. Board-certified nephrologist, as described in the video and on the channel Sean Hashmi, MD Background

Episode notes and full video

The label's dosing schedule

The label says Ozempic is injected subcutaneously once weekly, on the same day each week, at any time of day, with or without meals [1]. It starts at 0.25 mg once weekly for 4 weeks, which is not a maintenance dose, and then goes to 0.5 mg once weekly. For the kidney indication, the label says to increase to 1 mg once weekly after at least 4 weeks on the 0.5 mg dose [1].

For glycemic control alone, the label lists maintenance doses of 0.5 mg, 1 mg or 2 mg, with each step taken only after at least 4 weeks on the current dose and 2 mg as the maximum [1]. FLOW tested 1 mg, and the label writes the kidney indication at 1 mg [1][2].

If a dose is missed, the label says to administer it within 5 days of the missed dose [1].

Does kidney function change the dose?

No. The label recommends no dose adjustment for renal impairment and reports no clinically relevant change in semaglutide exposure in subjects with renal impairment, including kidney failure [1].

Kidney function is still part of the safety picture. The label carries a warning for acute kidney injury due to volume depletion, with postmarketing reports of injury sometimes requiring hemodialysis, mostly in patients who had nausea, vomiting or diarrhea causing dehydration [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dose initiation and escalation [1].

FLOW enrolled people with an eGFR from 25 up to 75 [2].

Questions worth asking

Choose the questions you want to keep

Side effects that matter for this use

Gastrointestinal effects are the main tolerability issue. In the pooled placebo-controlled Ozempic trials in type 2 diabetes, any GI adverse reaction occurred in 32.7% on 0.5 mg and 36.4% on 1 mg versus 15.3% on placebo; nausea in 15.8% and 20.3% versus 6.1%; and treatment was stopped for GI reasons in 3.1% and 3.8% versus 0.4% [1]. Severe GI reactions occurred in 0.4% at 0.5 mg and 0.8% at 1 mg versus 0% on placebo [1]. In FLOW, safety data collection was limited to serious events and selected predefined categories, and no new serious or severe adverse reactions were identified [1].

Other label points that bear on a kidney-protection decision:

  • The label says Ozempic is not recommended in patients with severe gastroparesis [1].
  • Acute pancreatitis has been reported with GLP-1 receptor agonists including Ozempic, and the label says to discontinue if pancreatitis is suspected [1].
  • Diabetic retinopathy complications occurred in 3.0% versus 1.8% in a 2-year cardiovascular trial, and 8.2% versus 5.2% among patients with retinopathy at baseline; the label says patients with a history of diabetic retinopathy should be monitored [1].
  • The boxed warning covers thyroid C-cell tumors in rodents, with human risk unknown; Ozempic is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 [1].
  • Ozempic delays gastric emptying; the label advises caution with oral medicines and says clinical pharmacology trials did not show a clinically relevant effect on absorption of oral medicines [1].

How it compares with SGLT2 inhibitors

The SGLT2 inhibitor kidney trials used different populations, entry criteria and composite endpoints from FLOW, so their percentages cannot be lined up against FLOW's 18.7% versus 23.2%. DAPA-CKD enrolled 4,304 people with an eGFR of 25 to 75 and a urine albumin-to-creatinine ratio of 200 to 5,000, and found the primary composite in 9.2% on dapagliflozin versus 14.5% on placebo (HR 0.61, 95% CI 0.51 to 0.72; number needed to treat 19), with similar effects in people with and without type 2 diabetes [4]. EMPA-KIDNEY, with 6,609 patients, reported a hazard ratio of 0.72 (95% CI 0.64 to 0.82) for kidney disease progression or cardiovascular death [5].

Oral semaglutide and compounded semaglutide

The Rybelsus and Ozempic tablets label lists glycemic control and reduction of major adverse cardiovascular events; it does not include the kidney indication [3]. FLOW tested subcutaneous semaglutide 1 mg once weekly [2].

Compounded semaglutide is not FDA-approved, and FDA does not review it for safety, effectiveness or quality before it is marketed [6].

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the label, what is the kidney-indication dose of Ozempic reached after at least 4 weeks on 0.5 mg?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Frequently asked questions

Is Ozempic FDA-approved for kidney protection?
Yes, for adults with type 2 diabetes and chronic kidney disease. The label effective 2026-06-01 includes an indication to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in that group [1].
What dose of Ozempic was used for kidney protection?
1 mg once weekly, reached after at least 4 weeks on 0.5 mg, which is what the label specifies for the kidney indication [1]. FLOW used that same 1 mg dose [2].
Does low kidney function change the Ozempic dose?
No. The label recommends no dose adjustment for renal impairment [1]. FLOW enrolled patients with an eGFR from 25 up to 75 mL/min/1.73 m² [2].
Can Ozempic protect the kidneys in people without diabetes?
The Ozempic kidney indication is limited to adults with type 2 diabetes and chronic kidney disease [1], and FLOW enrolled only that population [2].
Can oral semaglutide be used instead for kidney protection?
The Rybelsus and Ozempic tablets label covers glycemic control and cardiovascular risk reduction, not the kidney indication [3]. FLOW tested the weekly injection [2].
What is the main safety concern on a kidney-protection prescription?
Volume depletion. The label warns about acute kidney injury from dehydration due to nausea, vomiting or diarrhea and says to monitor renal function in patients reporting those reactions, especially during dose initiation and escalation [1]. Nausea occurred in 20.3% on 1 mg versus 6.1% on placebo in pooled trials [1].

References

Show all 8 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  2. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.
  3. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  4. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
  5. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127.
  6. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA.
  7. Reddit participants. Anyone else on Ozempic and see improved egfr? (r/CKD). Accessed 2026-11-11.
  8. Sean Hashmi, MD. Why This Ozempic Trial Was Stopped Early. Accessed 2026-11-11.
Evidence overview for Ozempic for Kidney Protection: Approved Use, Dosing and FLOW